moatshark My

All holdings

Dianthus Therapeutics

DNTH

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
1
In their latest 13F (Q3 2026)
See who
Value held
$910k
Combined value at quarter end
Last quarter
1 bought
0 sold or trimmed
Price at Q2 ’26 end
$97.48
+16.2% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

+16.2%Q2 ’26
Q2 ’26: +16.2%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

0Q4 ’23
0Q1 ’24
0Q2 ’24
0Q3 ’24
0Q4 ’24
0Q1 ’25
0Q2 ’25
0Q3 ’25
0Q4 ’25
1Q1 ’26
1Q2 ’26
0Q3 ’26
Q4 ’23: 0; Q1 ’24: 0; Q2 ’24: 0; Q3 ’24: 0; Q4 ’24: 0; Q1 ’25: 0; Q2 ’25: 0; Q3 ’25: 0; Q4 ’25: 0; Q1 ’26: 1; Q2 ’26: 1; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Dianthus Therapeutics.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Dianthus Therapeutics
Polen Capital Management0.0%$910k$910kAdded +127%2 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Dianthus Therapeutics
Bought or soldFiling
17 Sep 2026Carr EdwardCHIEF ACCOUNTING OFFICER▼ Sold7,928$100.43$796kForm 4
17 Sep 2026Carr EdwardCHIEF ACCOUNTING OFFICER▼ Sold6,771$101.37$686kForm 4
17 Sep 2026Carr EdwardCHIEF ACCOUNTING OFFICER▼ Sold3,501$102.39$358kForm 4
17 Sep 2026Carr EdwardCHIEF ACCOUNTING OFFICER▼ Sold1,100$103.20$114kForm 4
17 Sep 2026Carr EdwardCHIEF ACCOUNTING OFFICER▼ Sold700$104.39$73kForm 4
1 Sep 2026Randhawa SimratEVP, Head of R&D▼ Sold13,309$106.74$1.4mForm 4
1 Sep 2026Randhawa SimratEVP, Head of R&D▼ Sold7,215$106.25$767kForm 4
1 Sep 2026Randhawa SimratEVP, Head of R&D▼ Sold2,600$105.19$273kForm 4
19 Aug 2026Read SimonDirector▼ Sold2,778$117.55$327kForm 4
10 Aug 2026Veness Adam MSVP, General Counsel and Sec.▼ Sold16,167$110.38$1.8mForm 4
10 Aug 2026Mcgeorge AnneDirector▼ Sold2,800$108.38$303kForm 4
10 Aug 2026Mcgeorge AnneDirector▼ Sold1,800$109.30$197kForm 4
10 Aug 2026Mcgeorge AnneDirector▼ Sold1,450$107.58$156kForm 4
10 Aug 2026Mcgeorge AnneDirector▼ Sold1,000$110.64$111kForm 4
10 Aug 2026Read SimonDirector▼ Sold831$108.95$91kForm 4
10 Aug 2026Read SimonDirector▼ Sold737$108.17$80kForm 4
10 Aug 2026Mcgeorge AnneDirector▼ Sold700$111.41$78kForm 4
10 Aug 2026Read SimonDirector▼ Sold470$111.05$52kForm 4
10 Aug 2026Read SimonDirector▼ Sold397$111.77$44kForm 4
10 Aug 2026Read SimonDirector▼ Sold272$109.96$30kForm 4

About the company

Sector
Health care · Pharmaceutical Preparations
Incorporated in
Delaware
Financial year ends
31 December
Shares outstanding
56m at 3 Aug 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$0k2016
$0k2017
$0k2018
$0k2019
2020
$1.5m2021
$6.4m2022
$2.8m2023
$6.2m2024
$2.0m2025
2016: $0k; 2017: $0k; 2018: $0k; 2019: $0k; 2020: not held; 2021: $1.5m; 2022: $6.4m; 2023: $2.8m; 2024: $6.2m; 2025: $2.0m
Dianthus Therapeutics revenue and net income by year
YearRevenueNet income
2025$2.0m−$162m
2024$6.2m−$85.0m
2023$2.8m−$43.5m
2022$6.4m−$28.5m
2021$1.5m−$13.1m
2020–−$74.9m
2019$0k−$76.8m
2018$0k−$57.5m
2017$0k−$35.5m
2016$0k−$9.4m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.